Ballentine Partners, LLC Bristol Myers Squibb CO Transaction History
Ballentine Partners, LLC
- $5.39 Billion
- Q2 2024
A detailed history of Ballentine Partners, LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Ballentine Partners, LLC holds 35,646 shares of BMY stock, worth $1.9 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
35,646
Previous 47,391
24.78%
Holding current value
$1.9 Million
Previous $2.57 Million
42.41%
% of portfolio
0.03%
Previous 0.05%
Shares
28 transactions
Others Institutions Holding BMY
# of Institutions
2,428Shares Held
1.5BCall Options Held
29.7MPut Options Held
32.2M-
Vanguard Group Inc Valley Forge, PA187MShares$9.92 Billion0.15% of portfolio
-
Black Rock Inc. New York, NY159MShares$8.44 Billion0.15% of portfolio
-
State Street Corp Boston, MA91.4MShares$4.86 Billion0.17% of portfolio
-
Jpmorgan Chase & CO New York, NY74.6MShares$3.97 Billion0.27% of portfolio
-
Charles Schwab Investment Management Inc San Francisco, CA59.1MShares$3.14 Billion0.47% of portfolio
About BRISTOL MYERS SQUIBB CO
- Ticker BMY
- Exchange NYSE
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 2,126,160,000
- Market Cap $113B
- Description
- Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...